Top-Rated StocksTop-RatedNYSE:BHVN Biohaven (BHVN) Stock Price, News & Analysis $46.81 +0.51 (+1.10%) (As of 11/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Biohaven Stock (NYSE:BHVN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Biohaven alerts:Sign Up Key Stats Today's Range$44.95▼$47.1750-Day Range$35.75▼$53.7352-Week Range$26.80▼$62.21Volume785,377 shsAverage Volume1.13 million shsMarket Capitalization$4.73 billionP/E RatioN/ADividend YieldN/APrice Target$63.42Consensus RatingBuy Company OverviewBiohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.Read More… Top "Sleeping Giant" Crypto In The Market Now (Ad)Top "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your financial future. Click here to discover our #1 crypto pick before it's too late Biohaven Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks78th Percentile Overall ScoreBHVN MarketRank™: Biohaven scored higher than 78% of companies evaluated by MarketBeat, and ranked 278th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingBiohaven has received a consensus rating of Buy. The company's average rating score is 3.07, and is based on 13 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBiohaven has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Biohaven's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Biohaven are expected to grow in the coming year, from ($8.87) to ($6.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biohaven is -5.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biohaven is -5.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiohaven has a P/B Ratio of 8.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Biohaven's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.05% of the outstanding shares of Biohaven have been sold short.Short Interest Ratio / Days to CoverBiohaven has a short interest ratio ("days to cover") of 9.5.Change versus previous monthShort interest in Biohaven has recently decreased by 1.93%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiohaven does not currently pay a dividend.Dividend GrowthBiohaven does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.05% of the outstanding shares of Biohaven have been sold short.Short Interest Ratio / Days to CoverBiohaven has a short interest ratio ("days to cover") of 9.5.Change versus previous monthShort interest in Biohaven has recently decreased by 1.93%, indicating that investor sentiment is improving. News and Social Media2.6 / 5News Sentiment0.72 News SentimentBiohaven has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Biohaven this week, compared to 5 articles on an average week.Search InterestOnly 4 people have searched for BHVN on MarketBeat in the last 30 days. This is a decrease of -79% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Biohaven to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Biohaven insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,220,920.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders16.00% of the stock of Biohaven is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions88.78% of the stock of Biohaven is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Biohaven's insider trading history. Receive BHVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biohaven and its competitors with MarketBeat's FREE daily newsletter. Email Address BHVN Stock News HeadlinesBiotech-stock investing has one tough test for success — and it’s about to get easierNovember 18 at 7:55 PM | msn.comBiohaven stock target cut by analyst on model updatesNovember 15, 2024 | uk.investing.comTop "Sleeping Giant" Crypto In The Market NowTop "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your financial future. November 21, 2024 | Crypto 101 Media (Ad)Biohaven Ltd. (BHVN) Receives a Buy from Morgan StanleyNovember 15, 2024 | markets.businessinsider.comAandelen Biohaven stijgen na verhoging koersdoel door TD Cowen naar $75November 14, 2024 | nl.investing.comBiohaven Ltd.: Promising Prospects and Financial Stability Drive Buy RatingNovember 14, 2024 | markets.businessinsider.comBiohaven Ltd.: Strong Buy Rating Driven by Promising Pipeline Progress and Strategic ResubmissionsNovember 14, 2024 | markets.businessinsider.comBiohaven Ltd.: Biohaven Reports Third Quarter 2024 Financial Results and Recent Business DevelopmentsNovember 13, 2024 | finanznachrichten.deSee More Headlines BHVN Stock Analysis - Frequently Asked Questions How have BHVN shares performed this year? Biohaven's stock was trading at $42.80 at the start of the year. Since then, BHVN stock has increased by 9.4% and is now trading at $46.81. View the best growth stocks for 2024 here. How were Biohaven's earnings last quarter? Biohaven Ltd. (NYSE:BHVN) posted its quarterly earnings results on Tuesday, November, 12th. The company reported ($1.70) earnings per share for the quarter, missing the consensus estimate of ($1.67) by $0.03. When did Biohaven IPO? Biohaven (BHVN) raised $124 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 8,300,000 shares at $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital acted as the underwriters for the IPO and William Blair and Needham & Company were co-managers. Who are Biohaven's major shareholders? Top institutional shareholders of Biohaven include Stifel Financial Corp (6.44%), Janus Henderson Group PLC (6.16%), State Street Corp (3.22%) and FMR LLC (1.95%). Insiders that own company stock include Vlad Coric, Gregory Bailey, Matthew Buten, John W Childs, George C Clark, Irina Antonijevic, Julia P Gregory, Elyse Stock, James Engelhart and Declan Doogan. View institutional ownership trends. How do I buy shares of Biohaven? Shares of BHVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Biohaven own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biohaven investors own include NVIDIA (NVDA), Humana (HUM), Invesco QQQ (QQQ), Meta Platforms (META), American Water Works (AWK), Broadcom (AVGO) and Voyager Therapeutics (VYGR). Company Calendar Last Earnings11/12/2024Today11/20/2024Fiscal Year End12/31/2024Next Earnings (Estimated)3/06/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:BHVN Previous SymbolNASDAQ:BHVN CUSIPN/A CIK1689813 Webwww.biohavenpharma.com Phone203-404-0410FaxN/AEmployees239Year FoundedN/APrice Target and Rating Average Stock Price Target$63.42 High Stock Price Target$76.00 Low Stock Price Target$54.00 Potential Upside/Downside+35.5%Consensus RatingBuy Rating Score (0-4)3.07 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($9.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-408,170,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-225.12% Return on Assets-158.89% Debt Debt-to-Equity RatioN/A Current Ratio2.89 Quick Ratio2.89 Sales & Book Value Annual Sales$462.51 million Price / Sales10.23 Cash FlowN/A Price / Cash FlowN/A Book Value$5.34 per share Price / Book8.77Miscellaneous Outstanding Shares101,120,000Free Float84,942,000Market Cap$4.73 billion OptionableOptionable Beta1.31 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NYSE:BHVN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biohaven Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biohaven With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.